Can I Take Omega-3 (EPA/DHA) with Jardiance (Empagliflozin)?

What the Interaction Actually Is (and Is Not)

This combination does not interact at the liver-enzyme level. Neither empagliflozin nor omega-3 fatty acids are metabolized by CYP450 enzymes in ways that cause one drug to raise or lower the blood concentration of the other. Empagliflozin is cleared primarily by UGT1A3 and UGT2B7 glucuronidation, and EPA/DHA are oxidized through beta-oxidation pathways. No pharmacokinetic collision exists.

What does exist is a pharmacodynamic overlap: both agents influence triglycerides and, through separate mechanisms, blood pressure and platelet function.

How Empagliflozin Affects Lipids

Empagliflozin lowers triglycerides modestly. In the EMPA-REG OUTCOME trial, which enrolled 7,020 adults with type 2 diabetes and established cardiovascular disease, empagliflozin-treated participants showed small reductions in triglycerides compared with placebo over a median follow-up of 3.1 years. The mechanism involves reduced hepatic VLDL secretion driven by improved insulin sensitivity and increased fatty-acid oxidation in the setting of mild ketonemia.

How Omega-3 Fatty Acids Affect Lipids

High-dose prescription omega-3 (4 g/day icosapentaenoic acid as icosapent ethyl, brand name Vascepa) lowers triglycerides by 25-30% and, per the REDUCE-IT trial, cuts major adverse cardiovascular events by 25% in adults with elevated triglycerides on statins. Over-the-counter fish oil at 1-2 g EPA+DHA per day produces a smaller but real 10-15% triglyceride reduction.

When you take both agents together, the triglyceride drop is additive. For a woman with PCOS or metabolic syndrome where triglycerides are already elevated, this additive effect is often a clinical goal rather than a hazard. The concern arises only if triglycerides fall so low that lipid-panel interpretation becomes tricky, which is unusual in practice.

The Antiplatelet Angle

EPA and DHA reduce platelet aggregation by competing with arachidonic acid in the thromboxane pathway. At dietary doses (under 1 g/day), the clinical bleeding signal is negligible. Above 2 g EPA+DHA per day, studies begin to show modest prolongation of bleeding time, though the FDA concluded in 2020 that high-dose omega-3 does not substantially increase clinically significant bleeding risk in most adults not already on anticoagulants.

Empagliflozin has no direct antiplatelet mechanism. The caution here applies if you are also on aspirin, a NSAID, or an anticoagulant. In that scenario, adding >2 g EPA+DHA per day creates a three-way pharmacodynamic stack that warrants a conversation with your prescriber.

Women-Specific Physiology: Why This Combination Comes Up More Often in Female Patients

Women are not a monolith, and the relevance of this drug-supplement combination shifts substantially across life stage.

Reproductive Years and PCOS

PCOS affects 8-13% of women of reproductive age and carries a well-documented dyslipidemia profile: elevated triglycerides, low HDL, and small dense LDL particles. Empagliflozin is not FDA-approved for PCOS, but it is prescribed off-label for insulin resistance in this group. Omega-3 supplementation is one of the more evidence-backed dietary interventions for PCOS-associated hypertriglyceridemia. A 2018 meta-analysis in Reproductive BioMedicine Online found omega-3 supplementation significantly reduced triglycerides and fasting insulin in women with PCOS compared with placebo. Taking both agents together in this population is therefore common and generally intentional.

Perimenopause and Menopause

The estrogen withdrawal of perimenopause shifts lipid metabolism toward higher triglycerides and a more atherogenic LDL pattern. The Menopause Society (NAMS) notes that cardiovascular risk accelerates in the years following the final menstrual period. Women in this life stage who develop type 2 diabetes or heart failure may be prescribed empagliflozin, and many will already be taking fish oil for heart protection. The additive triglyceride benefit in this population is clinically meaningful. Blood pressure monitoring remains relevant because both agents exert modest antihypertensive effects: empagliflozin reduces systolic blood pressure by roughly 3-4 mmHg through osmotic diuresis, and high-dose omega-3 reduces systolic blood pressure by approximately 4 mmHg in hypertensive adults per a 2014 Cochrane review.

Trying to Conceive and Pregnancy

This section carries a hard safety boundary. Empagliflozin is contraindicated in the second and third trimesters of pregnancy. Animal data show fetal renal toxicity at clinically relevant exposures. The FDA label for empagliflozin advises discontinuing the drug when pregnancy is confirmed. First-trimester human safety data are limited; the precautionary standard is to stop as soon as pregnancy is known.

If you are trying to conceive and taking empagliflozin for type 2 diabetes or heart failure, discuss transition to a pregnancy-compatible agent (insulin is the established standard for glycemic control in pregnancy) with your clinician before attempting conception.

Omega-3 EPA/DHA in pregnancy is a different story. ACOG supports adequate omega-3 intake during pregnancy for fetal neurodevelopment. Most prenatal vitamins contain DHA. At dietary doses, omega-3 carries no fetal safety concern.

Contraception note: Because empagliflozin poses fetal risk, women of reproductive age taking this drug who do not wish to become pregnant should use reliable contraception. No specific contraceptive type is contraindicated, but note that SGLT2 inhibitors do not interfere with hormonal contraceptive efficacy.

Lactation

Human data on empagliflozin transfer into breast milk are absent. Animal studies show drug presence in milk and effects on nursing offspring kidneys. The FDA label advises against use during breastfeeding. Omega-3 supplementation during breastfeeding is generally safe and may support infant brain development.

Dose and Timing: Is There a Separation Window?

No dose-separation window is required. Because the interaction is pharmacodynamic rather than pharmacokinetic, the timing of each dose relative to the other does not change the interaction risk. Empagliflozin is typically taken in the morning. Fish oil can be taken with any meal to reduce the GI upset that some women notice when taking it on an empty stomach.

If you are using prescription-strength icosapentaenoic acid (4 g/day Vascepa or Lovaza-class omega-3 carboxylic acids), your prescriber should already be monitoring your lipid panel and should be aware of all concurrent medications and supplements.

Monitoring: What to Watch and When

The following framework applies specifically to women taking empagliflozin plus omega-3 EPA/DHA at doses above 1 g/day.

Lipid Panel

A fasting lipid panel every 6-12 months is reasonable. In women with PCOS, perimenopause-associated dyslipidemia, or baseline triglycerides above 500 mg/dL, quarterly monitoring in the first year of combination use helps confirm that additive lowering is not pushing triglycerides below the point where fat-soluble vitamin absorption is impaired (this is theoretical and rare but worth knowing).

Blood Pressure

Check at every clinical visit or at home monthly. Systolic reductions from empagliflozin plus high-dose omega-3 together can reach 6-8 mmHg, which is clinically meaningful in a woman already on an antihypertensive. If you notice lightheadedness on standing, tell your prescriber.

Bleeding Symptoms

At over-the-counter doses (under 2 g EPA+DHA per day), routine bleeding monitoring is not required. If you move to prescription-strength omega-3 and are also on aspirin or a blood thinner, report any unusual bruising, nosebleeds lasting more than 10 minutes, or heavy menstrual flow that is new or worsening.

Urinary Tract and Genital Infections

This monitoring point is specific to empagliflozin, not the omega-3 combination. SGLT2 inhibitors increase urinary glucose, raising the risk of urinary tract infections and vulvovaginal candidiasis. Women have a higher baseline UTI incidence than men, and this risk increases further on empagliflozin. Good genital hygiene and prompt reporting of symptoms matter.

Who This Combination Is Right For (and Who Should Pause)

Good Candidates

Women who stand to benefit from this combination include those with type 2 diabetes or heart failure on empagliflozin who also have hypertriglyceridemia above 150 mg/dL. Women with PCOS who are prescribed empagliflozin off-label for metabolic support. Women in perimenopause or post-menopause with established cardiovascular risk who are taking fish oil for secondary prevention alongside Jardiance for heart failure. These women benefit from the additive lipid and cardiovascular effects with manageable monitoring requirements.

Use Caution or Discuss First

Women on aspirin plus an anticoagulant who want to add high-dose (>2 g/day) omega-3 should review the full antiplatelet stack with their prescriber before starting. Women whose triglycerides are already below 75 mg/dL on empagliflozin alone may see limited additional benefit from high-dose omega-3 for lipid purposes, though cardiovascular benefits of icosapent ethyl appear partly triglyceride-independent per REDUCE-IT subgroup analyses.

Women who are pregnant or actively trying to conceive should stop empagliflozin and continue omega-3 at dietary doses.

Not Right For

Women in the second or third trimester of pregnancy. Breastfeeding women who cannot access an alternative agent for their diabetes or heart failure management.

Evidence Gaps: What We Do Not Know Yet

Women have been consistently under-represented in cardiovascular outcomes trials. In EMPA-REG OUTCOME, women made up only 28.5% of participants. In REDUCE-IT, women were approximately 28% of the trial population. This means the cardiovascular event-reduction data for both empagliflozin and high-dose icosapent ethyl are extrapolated from male-majority datasets to female patients, not directly established in women at the same level of confidence.

No trial has specifically examined the combination of empagliflozin plus omega-3 as a co-intervention in women. The interaction characterization here is based on the known pharmacology of each agent studied separately, not a head-to-head co-administration study. That is an honest limitation. The absence of a direct interaction trial does not suggest harm; it simply means the "safe" conclusion rests on mechanistic reasoning and clinical experience rather than a dedicated RCT.

Sex-specific pharmacokinetic data on empagliflozin show that women have approximately 14-18% higher empagliflozin AUC than men at the same dose, likely driven by body weight and renal function differences. Whether this modestly higher exposure changes the pharmacodynamic interaction with omega-3 has not been studied.

Practical Takeaways for Your Next Appointment

Bring your full supplement list, including the brand, dose of EPA and DHA listed separately on the label (not total fish oil), and how long you have been taking it. Your prescriber needs these specific numbers, not just "I take fish oil."

If you take more than 2 g EPA+DHA per day, confirm your prescriber knows. If you are in perimenopause, postmenopause, or have PCOS, mention that too, because lipid goals and cardiovascular risk stratification differ by hormonal status.

Ask for a fasting lipid panel at your next visit if you have not had one in the past 12 months. A baseline triglyceride level helps your clinician interpret the combined effect of both agents over time.

Dr. Maya Okafor, MD, WomanRx medical reviewer, notes: "In my clinical experience, women with PCOS on empagliflozin for metabolic insulin resistance and omega-3 for hypertriglyceridemia represent the group where this combination is most clearly intentional and most worth tracking with a regular lipid panel. The additive triglyceride effect is real and useful, not a reason to avoid the combination."

If your triglycerides drop below 50 mg/dL on the combination, flag it for your clinician. This is uncommon but is worth knowing because very low triglycerides can occasionally signal malnutrition or other metabolic shifts in women with eating history or significant caloric restriction.